329 related articles for article (PubMed ID: 10942797)
21. A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.
Zhang S; Endo S; Koga H; Ichikawa T; Feng X; Onda K; Washiyama K; Kumanishi T
Jpn J Cancer Res; 1996 Sep; 87(9):900-7. PubMed ID: 8878451
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
[TBL] [Abstract][Full Text] [Related]
23. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
24. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
25. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Faderl S; Kantarjian HM; Estey E; Manshouri T; Chan CY; Rahman Elsaied A; Kornblau SM; Cortes J; Thomas DA; Pierce S; Keating MJ; Estrov Z; Albitar M
Cancer; 2000 Nov; 89(9):1976-82. PubMed ID: 11064355
[TBL] [Abstract][Full Text] [Related]
27. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
[TBL] [Abstract][Full Text] [Related]
28. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
[TBL] [Abstract][Full Text] [Related]
29. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M; Calvano JE; Ho GH; Orlow I; Cordón-Cardó C; Borgen PI; Van Zee KJ
Cancer Genet Cytogenet; 2001 Mar; 125(2):131-8. PubMed ID: 11369056
[TBL] [Abstract][Full Text] [Related]
31. p16 is a major inactivation target in hepatocellular carcinoma.
Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
[TBL] [Abstract][Full Text] [Related]
32. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
[TBL] [Abstract][Full Text] [Related]
33. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors.
López-Guerrero JA; Pellín A; Noguera R; Carda C; Llombart-Bosch A
Lab Invest; 2001 Jun; 81(6):803-14. PubMed ID: 11406642
[TBL] [Abstract][Full Text] [Related]
34. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia.
Hatta Y; Hirama T; Miller CW; Yamada Y; Tomonaga M; Koeffler HP
Blood; 1995 May; 85(10):2699-704. PubMed ID: 7742529
[TBL] [Abstract][Full Text] [Related]
35. Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors.
Obana K; Yang HW; Piao HY; Taki T; Hashizume K; Hanada R; Yamamoto K; Tanaka Y; Toyoda Y; Takita J; Tsuchida Y; Hayashi Y
Int J Oncol; 2003 Oct; 23(4):1151-7. PubMed ID: 12963998
[TBL] [Abstract][Full Text] [Related]
36. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
37. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
38. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Ishii N; Maier D; Merlo A; Tada M; Sawamura Y; Diserens AC; Van Meir EG
Brain Pathol; 1999 Jul; 9(3):469-79. PubMed ID: 10416987
[TBL] [Abstract][Full Text] [Related]
39. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
40. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
